Wilkins Investment Counsel Inc. held its position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, Holdings Channel reports. The firm owned 4,075 shares of the medical research company’s stock at the end of the second quarter. Wilkins Investment Counsel Inc.’s holdings in Amgen were worth $620,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Acadian Asset Management LLC increased its position in Amgen by 0.6% in the first quarter. Acadian Asset Management LLC now owns 8,268 shares of the medical research company’s stock valued at $1,239,000 after buying an additional 51 shares during the period. P.R. Herzig & Co. Inc. increased its position in Amgen by 107.7% in the first quarter. P.R. Herzig & Co. Inc. now owns 7,975 shares of the medical research company’s stock valued at $1,196,000 after buying an additional 4,135 shares during the period. First Financial Corp IN increased its position in Amgen by 1.9% in the first quarter. First Financial Corp IN now owns 3,573 shares of the medical research company’s stock valued at $536,000 after buying an additional 65 shares during the period. McQueen Ball & Associates Inc. increased its position in Amgen by 1.7% in the first quarter. McQueen Ball & Associates Inc. now owns 10,642 shares of the medical research company’s stock valued at $1,596,000 after buying an additional 182 shares during the period. Finally, Sigma Planning Corp increased its position in Amgen by 7.6% in the first quarter. Sigma Planning Corp now owns 6,278 shares of the medical research company’s stock valued at $941,000 after buying an additional 442 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 166.81 on Friday. The stock’s 50 day moving average price is $171.68 and its 200-day moving average price is $161.02. The firm has a market cap of $124.83 billion, a PE ratio of 17.07 and a beta of 0.87. Amgen Inc. has a 52-week low of $138.06 and a 52-week high of $176.85.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. During the same quarter last year, the business posted $2.57 EPS. The company’s revenue was up 5.9% on a year-over-year basis. On average, equities research analysts anticipate that Amgen Inc. will post $11.36 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were paid a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio is 40.90%.
AMGN has been the topic of several research reports. Vetr downgraded Amgen from a “buy” rating to a “hold” rating and set a $159.50 target price on the stock. in a research report on Tuesday, June 7th. Bank of America Corp. restated a “hold” rating and issued a $182.00 target price on shares of Amgen in a research report on Wednesday, June 8th. BMO Capital Markets restated an “outperform” rating and issued a $186.00 target price on shares of Amgen in a research report on Thursday, June 9th. Leerink Swann reaffirmed a “market perform” rating and issued a $186.00 price target on shares of Amgen in a report on Thursday, June 9th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $202.00 price target on shares of Amgen in a report on Wednesday, June 15th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $185.06.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.